Is Ingrezza Quality Of Life Data Altering The Investment Case For Neurocrine Biosciences (NBIX)?

Simply Wall St.11-12

Neurocrine Biosciences reported new survey and Phase 4 KINECT PRO data indicating that adults with tardive dyskinesia taking INGREZZA experienced fewer work and school disruptions and broad quality of...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment